Zobrazeno 1 - 5
of 5
pro vyhledávání: '"329"'
Autor:
Yasushi Miyazaki, Yoshihiro Hatta, Toru Sakura, Noriyoshi Iriyama, Hiroshi Handa, Masatomo Takahashi, Hisashi Sakamaki, Tomohiko Taki, Norio Asou, Shunichiro Yamaguchi, Tomoya Maeda, Shinya Satou, Shuichi Miyawaki, Sumihisa Honda, Shigeki Ohtake, Tomoki Naoe, Masafumi Taniwaki
Publikováno v:
Blood. 122:2608-2608
Background Immunophenotyping is a standard diagnostic procedure in leukemia, but unlike cytogenetic classifications, which are reliable indicators for prognostic interpretation, immunophenotyping has, thus far, yielded inconsistent results. Recently,
Publikováno v:
Blood. 138:1944-1944
Background: Rapid advances in the understanding of the biology of MDS and AML have led to novel therapeutic interventions that have increased the clinical complexity of decision making in patient care. This study sought to quantify professional pract
Autor:
Mengyang Di, Xiaomei Ma, Rong Wang, Scott F. Huntington, Natalia Neparidze, Rory M. Shallis, Nikolai A. Podoltsev, Amer M. Zeidan
Publikováno v:
Blood. 138:282-282
Introduction: Patients (pts) with chronic-phase chronic myeloid leukemia (CML) are recommended to have quantitative BCR-ABL1 polymerase chain reaction (qPCR) testing every 3 months (mo) during the 1 st year of tyrosine kinase inhibitor (TKI) treatmen
Autor:
Evandro D. Bezerra, Brenda M. Sandmaier, Linde M. Morsink, Megan Othus, H. Joachim Deeg, H. Gary Schoch, Brent L. Wood, Min Fang, Frederick R. Appelbaum, Roland B. Walter
Publikováno v:
Blood. 134:321-321
Background:Myeloablative allogeneic hematopoietic cell transplantation (HCT) is a common post-remission treatment strategy for medically fit adults with acute myeloid leukemia (AML) in morphologic remission. Several conditioning regimens have been ut
Autor:
Wolfgang Kern, Karolína Perglerová, Susanne Schnittger, Manja Meggendorfer, Tamara Alpermann, Claudia Haferlach, Torsten Haferlach, Niroshan Nadarajah
Publikováno v:
Web of Science
Background: NPM1 mutations (mut) are considered the most frequent mutations in de novo acute myeloid leukemia (AML) and have been suggested as provisional entity in the WHO classification 2008. It has become clear that nearly all NPM1mut AML have add